Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.84 - $1.22 $922 - $1,339
1,098 Added 41.09%
3,770 $4,000
Q3 2023

Nov 14, 2023

BUY
$0.82 - $1.42 $884 - $1,532
1,079 Added 67.73%
2,672 $2,000
Q2 2023

Aug 14, 2023

BUY
$1.09 - $9.93 $1,735 - $15,808
1,592 Added 159200.0%
1,593 $1,000
Q1 2023

May 15, 2023

SELL
$7.77 - $12.47 $7 - $12
-1 Reduced 50.0%
1 $0
Q4 2022

Feb 14, 2023

SELL
$5.52 - $8.48 $121 - $186
-22 Reduced 91.67%
2 $0
Q3 2022

Nov 14, 2022

BUY
$4.75 - $8.01 $114 - $192
24 New
24 $0
Q2 2022

Aug 15, 2022

SELL
$2.21 - $5.56 $2,161 - $5,437
-978 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$5.07 - $13.68 $13,227 - $35,691
-2,609 Reduced 72.73%
978 $5,000
Q4 2021

Feb 14, 2022

BUY
$11.91 - $17.0 $32,966 - $47,056
2,768 Added 337.97%
3,587 $46,000
Q3 2021

Nov 15, 2021

BUY
$13.21 - $20.91 $2,853 - $4,516
216 Added 35.82%
819 $12,000
Q2 2021

Aug 16, 2021

BUY
$15.08 - $20.3 $9,093 - $12,240
603 New
603 $9,000

Others Institutions Holding RAIN

About Rain Therapeutics Inc.


  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.